We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Sensitive Nanozyme Test May Provide Rapid Point-of-Care Diagnosis of Ebola

By LabMedica International staff writers
Posted on 24 Sep 2015
Researchers have developed a simple low-cost Ebolavirus (EBOV) test based on detection technology using magnetic nanoparticles that has shown 100x higher sensitivity than the standard immunochromatographic ELISA gold strip test.

In a new study led by Xiyun Yan, professor at the Institute of Biophysics, Chinese Academy of Sciences (Beijing, China), a nanozyme strip test was developed that is similar to the gold strip test but instead uses Fe3O4 magnetic nanoparticles (nanozymes) that enhance the signal via their intrinsic enzyme-like activity. More...
Results showed 100x higher sensitivity than the gold strip test—the new test detects EBOV glycoprotein at concentrations as low as 1 nanogram/mL. Also, to concentrate the virus particles in the sample, the tube bottom is simply held against a magnet, so no expensive lab equipment is needed.

Early accurate detection is a key to controlling the Ebola outbreak as patients can then be isolated and treated. Current tests are either too expensive to be useful where they are most needed, or not sensitive enough to provide accurate diagnosis. PCR testing is highly sensitive but expensive and complicated, requiring specialized skills and equipment. Testing with the ELISA gold strip is inexpensive, but sensitivity is low.

“Our new strip test is a simple, one-step test that is cheap and easy to use, and provides a visible signal, which means people don’t need training to use it. We think it will be especially helpful in rural areas,” said Prof. Yan, “We’re very excited about our new nanozyme test, as it is much more sensitive and you don’t need any specialist equipment to get a quick, accurate result.” Her colleagues at the Chinese Center for Disease Control and Prevention (CDC) will field-test it in West Africa for its EBOV diagnostic and screening potential. The researchers are also developing automatic equipment to reduce risk of test contamination from hand-contact.

The nanozyme test is the result of an interdisciplinary collaboration of scientists and clinicians. The researchers are collaborating to develop this robust technology further as it can be applied for detection of other biological molecules, making it useful to diagnose additional infectious diseases and to potentially detect cancer tumors. It is also being tested for its potential to help in decontamination for wastewater treatment.

“We had an idea and talked to many people about it, and the result is a test that will overcome a problem,” said Prof. Yan, “We have built strong collaborations that have finally made this method successful, and we’re looking forward to applying it to many other areas.”

The study, by Duan D et al., was published online ahead of print 11 May 2015, in the journal Biosensors and Bioelectronics.

Related Links:

Chinese Academy of Sciences
Elsevier 



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.